| scholarly article | Q13442814 |
| review article | Q7318358 |
| P2093 | author name string | D Aletaha | |
| J Smolen | |||
| P433 | issue | 5 Suppl 39 | |
| P921 | main subject | rheumatoid arthritis | Q187255 |
| P304 | page(s) | S100-8 | |
| P577 | publication date | 2005-09-01 | |
| P1433 | published in | Clinical and Experimental Rheumatology | Q15759225 |
| P1476 | title | The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis | |
| P478 | volume | 23 |
| Q35136952 | "Design characteristics of the CORRONA CERTAIN study: a comparative effectiveness study of biologic agents for rheumatoid arthritis patients". |
| Q34486243 | A double-blind, randomized controlled trial to compare the effect of biannual peripheral magnetic resonance imaging, radiography and standard of care disease progression monitoring on pharmacotherapeutic escalation in rheumatoid and undifferentiated |
| Q41449525 | A randomised, double-blind trial to demonstrate bioequivalence of GP2013 and reference rituximab combined with methotrexate in patients with active rheumatoid arthritis |
| Q47259596 | A simplified version of Ankylosing Spondylitis Disease Activity Score (ASDAS) in patients with ankylosing spondylitis |
| Q34695603 | A three month controlled intervention of intermittent whole body vibration designed to improve functional ability and attenuate bone loss in patients with rheumatoid arthritis. |
| Q42121483 | Achieving comprehensive disease control in patients with early and established rheumatoid arthritis treated with adalimumab plus methotrexate versus methotrexate alone |
| Q34118958 | Adalimumab, a human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early rheumatoid arthritis: the HOPEFUL 1 study |
| Q84629497 | An association study of disease activity score components and patient satisfaction with overall health for early RA patients on non-biologic DMARD therapy |
| Q89336981 | An evaluation of the patient-administered Rheumatoid Arthritis Disease Activity Index for assessing disease activity during pregnancy |
| Q37658783 | Anaemia may add information to standardised disease activity assessment to predict radiographic damage in rheumatoid arthritis: a prospective cohort study. |
| Q90308268 | Anti-HLA Class II Antibodies Correlate with C-Reactive Protein Levels in Patients with Rheumatoid Arthritis Associated with Interstitial Lung Disease |
| Q34613898 | Applying science in practice: the optimization of biological therapy in rheumatoid arthritis |
| Q98564424 | Assessment of the association of baseline anti-CarbV and anti-MCV antibodies with response to treatment and radiographic progression in an RA population treated with either methotrexate or baricitinib: post-hoc analyses from RA-BEGIN |
| Q52983676 | Association of disease activity with acute exacerbation of interstitial lung disease during tocilizumab treatment in patients with rheumatoid arthritis: a retrospective, case-control study. |
| Q33945747 | B cell receptor signaling-based index as a biomarker for the loss of peripheral immune tolerance in autoreactive B cells in rheumatoid arthritis |
| Q55251974 | Baricitinib in Patients with Rheumatoid Arthritis and an Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs in United States and Rest of World: A Subset Analysis. |
| Q37604501 | Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study |
| Q37696609 | Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease-Modifying Antirheumatic Drug Treatment |
| Q92476178 | Barriers to treatment optimization and achievement of patients' goals: perspectives from people living with rheumatoid arthritis enrolled in the ArthritisPower registry |
| Q35440451 | Bone mineral density changes in patients with recent-onset rheumatoid arthritis |
| Q52807047 | Call for action: how to improve use of patient-reported outcomes to guide clinical decision making in rheumatoid arthritis. |
| Q35351313 | Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial |
| Q58614815 | Circulating S100 proteins effectively discriminate SLE patients from healthy controls: a cross-sectional study |
| Q92301896 | Citrullinated Inhibitor of DNA Binding 1 Is a Novel Autoantigen in Rheumatoid Arthritis |
| Q37690878 | Clinical disease activity and acute phase reactant levels are discordant among patients with active rheumatoid arthritis: acute phase reactant levels contribute separately to predicting outcome at one year |
| Q85522624 | Clinical outcome in patients with rheumatoid arthritis switched to tocilizumab after etanercept or infliximab failure |
| Q47822363 | Clinical relevance of P-glycoprotein activity on peripheral blood mononuclear cells and polymorphonuclear neutrophils to methotrexate in systemic lupus erythematosus patients. |
| Q82732841 | Clinical results for tocilizumab over one year in the clinical setting as assessed by CDAI (clinical disease activity index): CRP at week 12 and MMP-3 at week 24 are predictive factors for CDAI |
| Q55068670 | Common Evaluations of Disease Activity in Rheumatoid Arthritis Reach Discordant Classifications across Different Populations. |
| Q42734907 | Comparative effectiveness of adalimumab and etanercept for rheumatoid arthritis in the Brazilian Public Health System |
| Q59329016 | Comparative effectiveness of subcutaneous tocilizumab versus intravenous tocilizumab in a pan-European collaboration of registries |
| Q47367147 | Comparison between different disease activity scores in rheumatoid arthritis: an Egyptian multicenter study. |
| Q36386510 | Comparison of Care Provided in Practices With Nurse Practitioners and Physician Assistants Versus Subspecialist Physicians Only: A Cohort Study of Rheumatoid Arthritis |
| Q55177710 | Comparison of Disease Activity Score in 28 joints with ESR (DAS28), Clinical Disease Activity Index (CDAI), Health Assessment Questionnaire Disability Index (HAQ-DI) & Routine Assessment of Patient Index Data with 3 measures (RAPID3) for assessing d |
| Q36171802 | Comparison of composite measures of disease activity in an early seropositive rheumatoid arthritis cohort |
| Q48213354 | Comparison of physical function in early rheumatoid arthritis patients treated with biologics for 1 year who achieved clinical remission or low disease activity. |
| Q33783212 | Comparison of the Effects of a Pharmaceutical Industry Decision Guide and Decision Aids on Patient Choice to Intensify Therapy in Rheumatoid Arthritis |
| Q58204556 | Comparison of the clinical effectiveness of tumour necrosis factor inhibitors and abatacept after insufficient response to tocilizumab in patients with rheumatoid arthritis |
| Q88527641 | Comparison of the diagnostic potential of three anti-citrullinated protein antibodies as adjuncts to rheumatoid factor and CCP in a cohort of South African rheumatoid arthritis patients |
| Q37703462 | Comparison of the disease activity score using erythrocyte sedimentation rate and C-reactive protein in African Americans with rheumatoid arthritis |
| Q35788326 | Comprehensive appraisal of magnetic resonance imaging findings in sustained rheumatoid arthritis remission: a substudy |
| Q37292803 | Continuation of TNF blockade in patients with inflammatory rheumatic disease. An observational study on surgical site infections in 1,596 elective orthopedic and hand surgery procedures |
| Q92375526 | Cost-utility analysis of de-escalating biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis |
| Q45972867 | Cross-cultural adaptation and validation of the Thai version of the Rheumatoid Arthritis Disease Activity Index (RADAI). |
| Q36125286 | Cut-Offs and Response Criteria for the Hospital Universitario La Princesa Index (HUPI) and Their Comparison to Widely-Used Indices of Disease Activity in Rheumatoid Arthritis |
| Q89516727 | Depression: a common comorbidity in women with rheumatoid arthritis-results from an Austrian cross-sectional study |
| Q51847110 | Disability of Arm Shoulder and Hand Questionnaire in rheumatoid arthritis patients: relationship with disease activity, HAQ, SF-36 |
| Q90303881 | Discordance between the patient's and physician's global assessment in rheumatoid arthritis: Data from the REAL study-Brazil |
| Q35655764 | Disease activity in rheumatoid arthritis and the risk of cardiovascular events |
| Q33434163 | Disease activity level, remission and response in established rheumatoid arthritis: performance of various criteria sets in an observational cohort, treated with anti-TNF agents |
| Q37593506 | Drug interaction between methotrexate and salazosulfapyridine in Japanese patients with rheumatoid arthritis |
| Q92771523 | Early non-response to certolizumab pegol in rheumatoid arthritis predicts failure to achieve low disease activity at 1 year: data from a prospective observational study |
| Q92115742 | Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial |
| Q33652800 | Effectiveness and Costs of TNF-Alpha Blocker Use for Patients with Rheumatoid Arthritis |
| Q33932391 | Effectiveness of anti-tumor necrosis factor agents in the treatment of rheumatoid arthritis: observational study |
| Q30984829 | Effects of Achieving Target Measures in Rheumatoid Arthritis on Functional Status, Quality of Life, and Resource Utilization: Analysis of Clinical Practice Data |
| Q37143729 | Efficacy and Treatment Costs of Monotherapy with bDMARDs in the Treatment of Rheumatoid Arthritis in Patients Intolerant to or Inappropriate to Continue Treatment with Methotrexate |
| Q33638048 | Efficacy and safety at 24 weeks of daily clinical use of tofacitinib in patients with rheumatoid arthritis. |
| Q64990309 | Efficacy and safety of baricitinib for active rheumatoid arthritis in patients with an inadequate response to conventional synthetic or biological disease-modifying anti-rheumatic drugs: A meta-analysis of randomized controlled trials. |
| Q44337462 | Evaluation of Selected Rheumatoid Arthritis Activity Scores for Office-based Assessment |
| Q48014688 | Evaluation of an interferon gamma assay in the diagnosis of latent tuberculosis infection in patients with rheumatoid arthritis |
| Q37294493 | Evaluation of composite measures of treatment response without acute-phase reactants in patients with rheumatoid arthritis |
| Q33392167 | Evaluation of different methods used to assess disease activity in rheumatoid arthritis: analyses of abatacept clinical trial data |
| Q30566220 | Evaluation of disease activity in rheumatoid arthritis by Routine Assessment of Patient Index Data 3 (RAPID3) and its correlation to Disease Activity Score 28 (DAS28) and Clinical Disease Activity Index (CDAI): an Indian experience |
| Q51058021 | Evaluation of disease activity indices in Korean patients with rheumatoid arthritis. |
| Q33673930 | Evaluation of fatigue and its correlation with quality of life index, anxiety symptoms, depression and activity of disease in patients with psoriatic arthritis |
| Q33659257 | Evaluation of synovial angiogenesis in patients with rheumatoid arthritis using ⁶⁸Ga-PRGD2 PET/CT: a prospective proof-of-concept cohort study |
| Q34587397 | Evaluation of tocilizumab therapy in patients with rheumatoid arthritis based on FDG-PET/CT. |
| Q34238357 | Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity |
| Q39568753 | Fatigue, pain and patient global assessment responses to biological treatment are unpredictable, and poorly inter-connected in individual rheumatoid arthritis patients followed in the daily clinic |
| Q37177583 | GUEPARD treat-to-target strategy is significantly more efficacious than ESPOIR routine care in early rheumatoid arthritis according to patient-reported outcomes and physician global estimate |
| Q67224790 | General synovitis score and immunologic synovitis score reflect clinical disease activity in patients with advanced stage rheumatoid arthritis |
| Q33750044 | HDL cholesterol efflux capacity in rheumatoid arthritis patients: contributing factors and relationship with subclinical atherosclerosis |
| Q36334999 | Head-to-head comparison of aggressive conventional therapy and three biological treatments and comparison of two de-escalation strategies in patients who respond to treatment: study protocol for a multicenter, randomized, open-label, blinded-assesso |
| Q42755998 | Hematological Indices May Be Useful in the Diagnosis of Systemic Lupus Erythematosus and in Determining Disease Activity in Behçet's Disease |
| Q37672346 | Higher rates and clustering of abnormal lipids, obesity, and diabetes mellitus in psoriatic arthritis compared with rheumatoid arthritis |
| Q57809218 | I do not want to suppress the natural process of inflammation: new insights on factors associated with non-adherence in rheumatoid arthritis |
| Q42682599 | Incretins in patients with rheumatoid arthritis |
| Q88964013 | Influence of IL6R gene polymorphisms in the effectiveness to treatment with tocilizumab in rheumatoid arthritis |
| Q34929669 | Influence of patient characteristics on perceived risks and willingness to take a proposed anti-rheumatic drug |
| Q40926392 | Interplay between patient global assessment, pain, and fatigue and influence of other clinical disease activity measures in patients with active rheumatoid arthritis |
| Q57045247 | Introduction of a uniform record keeping practice for rheumatology clinics in Sri Lanka-an ILAR project |
| Q35595158 | Is the state of health of rheumatoid arthritis patients receiving adequate treatment, predictable? - Results of a survey. |
| Q38608695 | Long-Term Effectiveness of Adalimumab in Patients with Rheumatoid Arthritis: An Observational Analysis from the Corrona Rheumatoid Arthritis Registry |
| Q58761625 | Low mortality rate in Italian rheumatoid arthritis patients from a tertiary center: putative implication of a low anti-carbamylated protein antibodies prevalence |
| Q64987449 | Low-Dose Aspirin as Primary Prophylaxis for Cardiovascular Events in Rheumatoid Arthritis: An Italian Multicentre Retrospective Study. |
| Q38647845 | Mean cost per number needed to treat with tocilizumab plus methotrexate versus abatacept plus methotrexate in the treatment of rheumatoid arthritis in patients previously treated with methotrexate |
| Q33234551 | Measuring disease activity for rheumatoid arthritis |
| Q34208191 | Memory B cell subsets and plasmablasts are lower in early than in long-standing rheumatoid arthritis |
| Q35959354 | Meridian-sinew release therapy for the treatment of refractory rheumatoid arthritis. |
| Q42734608 | Methodological issues in the design of a rheumatoid arthritis activity score and its cut-offs |
| Q44461682 | Mortality in Italian patients with rheumatoid arthritis: evidence for a low mortality rate from cancer and infections in patients followed up at a tertiary center |
| Q37710757 | Novel Senescent Regulatory T-Cell Subset with Impaired Suppressive Function in Rheumatoid Arthritis. |
| Q36028729 | Older age at rheumatoid arthritis onset and comorbidities correlate with less Health Assessment Questionnaire-Disability Index and Clinical Disease Activity Index response to etanercept in the RADIUS 2 registry |
| Q37619717 | Outcome measures in inflammatory rheumatic diseases |
| Q38097709 | PROMs in inflammatory arthritis: moving from static to dynamic. |
| Q90411023 | Pain and Catastrophizing in Patients With Rheumatoid Arthritis: An Observational Cohort Study |
| Q87311281 | Pain-related comorbidities and medication absence as predictors of clinical remission in RA |
| Q38671016 | Patterns of circulatory and peripheral blood mononuclear cytokines in rheumatoid arthritis |
| Q46743986 | Perceived functional disabilities among rheumatoid arthritis patients |
| Q35249630 | Performance of the new 2011 ACR/EULAR remission criteria with tocilizumab using the phase IIIb study TAMARA as an example and their comparison with traditional remission criteria |
| Q35096472 | Peripheral blood CD4(+)CD25(+)CD127(low) regulatory T cells are significantly increased by tocilizumab treatment in patients with rheumatoid arthritis: increase in regulatory T cells correlates with clinical response. |
| Q94322276 | Phosphodiesterase 4 inhibitors for psoriatic arthritis |
| Q53837947 | Physician global assessments for disease activity in rheumatoid arthritis are all over the map! |
| Q41168364 | Power of national economy, disease control and employment status in patients with RA-an analytical multi-site ecological study |
| Q89647414 | Predicting Remission Among Patients With Rheumatoid Arthritis Starting Tocilizumab Monotherapy: Model Derivation and Remission Score Development |
| Q36974786 | Predicting low disease activity and remission using early treatment response to antitumour necrosis factor therapy in patients with rheumatoid arthritis: exploratory analyses from the TEMPO trial |
| Q47153964 | Psychometric properties of morning joint stiffness duration and severity measures in patients with moderately to severely active rheumatoid arthritis |
| Q47118941 | Psychometric properties of the single-item measure, severity of worst tiredness, in patients with moderately to severely active rheumatoid arthritis |
| Q33551313 | Racial and ethnic disparities in disease activity in patients with rheumatoid arthritis |
| Q35177630 | Randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of etanercept in patients with moderately active rheumatoid arthritis despite DMARD therapy |
| Q37501529 | Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2-year, observational, prospective ACTION study |
| Q36485737 | Recent paradigm shifts in the diagnosis and treatment of rheumatoid arthritis |
| Q90415263 | Red Cell Distribution Width in Rheumatoid arthritis |
| Q36819289 | Reductions in disease activity in the AMPLE trial: clinical response by baseline disease duration |
| Q41497288 | Relationship between serum calprotectin (S100A8/9) and clinical, laboratory and ultrasound parameters of disease activity in rheumatoid arthritis: A large cohort study. |
| Q35792839 | Reliability and validity of CDAI and SDAI indices in comparison to DAS-28 index in Moroccan patients with rheumatoid arthritis. |
| Q37399214 | Reliability and validity of the University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument |
| Q42010442 | Remission and low disease activity in a cohort of real-life patients with rheumatoid arthritis treated with first-line antitumour necrosis factor |
| Q34081946 | Remission in rheumatoid arthritis |
| Q90417661 | Repository Corticotropin Injection for Active Rheumatoid Arthritis Despite Aggressive Treatment: A Randomized Controlled Withdrawal Trial |
| Q61633956 | Residual disease activity in rheumatoid arthritis patients treated with subcutaneous biologic drugs that achieved remission or low disease activity: a longitudinal observational study |
| Q41931049 | Response to traditional disease-modifying anti-rheumatic drugs in indigent South Africans with early rheumatoid arthritis |
| Q64888081 | Retention of tocilizumab with and without methotrexate during maintenance therapy for rheumatoid arthritis: the ACTRA-RI cohort study. |
| Q33675569 | Rheumatoid arthritis in Jordan: a cross sectional study of disease severity and associated comorbidities |
| Q64988797 | Rheumatoid arthritis in remission : Decreased myostatin and increased serum levels of periostin. |
| Q47817154 | Rheumatoid arthritis-specific cardiovascular risk scores are not superior to general risk scores: a validation analysis of patients from seven countries |
| Q42340175 | Role of Serum cartilage oligomeric matrix protein (COMP) in the diagnosis of rheumatoid arthritis (RA): A case-control study |
| Q35755789 | Routine Assessment of Patient Index Data (RAPID3) and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Scores Yield Similar Information in 85 Korean Patients With Ankylosing Spondylitis Seen in Usual Clinical Care |
| Q35048395 | Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate |
| Q33591510 | Secukinumab treatment in rheumatoid arthritis is associated with incremental benefit in the clinical outcomes and HRQoL improvements that exceed minimally important thresholds |
| Q50234923 | Senescent T-Cells Promote Bone Loss in Rheumatoid Arthritis |
| Q36531030 | Serum levels of 14-3-3η protein supplement C-reactive protein and rheumatoid arthritis-associated antibodies to predict clinical and radiographic outcomes in a prospective cohort of patients with recent-onset inflammatory polyarthritis |
| Q36706945 | Significance of sex in achieving sustained remission in the consortium of rheumatology researchers of North America cohort of rheumatoid arthritis patients |
| Q39694655 | Stability of clinical outcome measures in rheumatoid arthritis patients with stable disease defined on the basis of the EULAR response criteria |
| Q90250659 | Successful long-term remission through tapering tocilizumab infusions: a single-center prospective study |
| Q42273153 | Sustained remission in rheumatoid arthritis: latest evidence and clinical considerations |
| Q40314992 | Switching profiles in a population-based cohort of rheumatoid arthritis receiving biologic therapy: results from the KOBIO registry. |
| Q45223225 | Test-retest reliability of the disease activity score 28 CRP (DAS28-CRP), the simplified disease activity index (SDAI) and the clinical disease activity index (CDAI) in rheumatoid arthritis when based on patient self-assessment of tender and swollen |
| Q92237119 | The World Health Organization Disability Assessment Schedule-2.0 (WHODAS 2.0) in a chronic pain population being considered for chronic opioid therapy |
| Q46742113 | The role of ultrasonography in monitoring long-standing rheumatoid arthritis: a pilot study |
| Q26765122 | The specialist physician's approach to rheumatoid arthritis in South Africa |
| Q49901596 | Tofacitinib Therapy for Rheumatoid Arthritis: A Direct Comparison Study between Biologic-naïve and Experienced Patients |
| Q39815843 | Treatment of rheumatoid arthritis (RA) in India-how and by whom: results from a speciality clinic-use of low-dose methotrexate (MTX) was inexplicably suboptimal. |
| Q41919866 | Treatment of rheumatoid arthritis with methotrexate alone and in combination with other conventional DMARDs using the T2T strategy. A cohort study |
| Q36984088 | Tumor necrosis factor antagonist responsiveness in a United States rheumatoid arthritis cohort |
| Q40548376 | Two-year radiographic and clinical outcomes from the Canadian Methotrexate and Etanercept Outcome study in patients with rheumatoid arthritis. |
| Q88960665 | Ultrasound assessment as predictor of disease relapse in children and adults with arthritis in clinical stable remission: new findings but still unmet needs |
| Q53124051 | Ultrasound-detected joint inflammation and B cell count: related variables for rituximab-treated RA patients? |
| Q37000165 | Use of biologics in rheumatoid arthritis: current and emerging paradigms of care |
| Q40253542 | Use of clinical disease activity index score for assessment of disease activity in rheumatoid arthritis patients: an Indian experience |
| Q36302285 | Usefulness of patients-reported outcomes in rheumatoid arthritis focus group |
| Q90235697 | Validity and interpretability of the QuickDASH in the assessment of hand disability in rheumatoid arthritis |
| Q51104726 | Visualization of DAS28, SDAI, and CDAI: the magic carpets of rheumatoid arthritis. |
| Q28074148 | What is the impact of biologic therapies on common co-morbidities in patients with rheumatoid arthritis? |
| Q82638877 | [Clinical outcome measures in hand- and finger joint osteoarthritis from the patient perspective] |
| Q83825059 | [Health-related quality of life (HRQoL) in rheumatoid arthritis] |
| Q48171338 | mRNA profilin identifies low levels of phosphatases dual-specific phosphatase-7 (DUSP7) and cell division cycle-25B (CDC25B) in patients with early arthritis. |
Search more.